logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Trastuzumab deruxtecan for unresectable or metastatic HER2-low (HR+/-) breast cancer – after chemotherapy

< Back

Trastuzumab deruxtecan for unresectable or metastatic HER2-low (HR+/-) breast cancer – after chemotherapy

Drugs

Cancer and Palliative Care

January 2021


Trastuzumab deruxtecan is in clinical development for the treatment of adults with HER2-low, hormone receptor (HR) positive or HR negative (HR+/-), unresectable and/or metastatic breast cancer (BC) who have previously been treated with chemotherapy. Metastatic BC (stage IV) is when the cancer has spread beyond the breast and nearby lymph nodes, whilst unresectable refers to cancer that cannot be treated by surgery. HER2 receptors help control how a healthy breast cell grows, divides, and repairs itself. In the case of IHC 0 and 1+ results or IHC+ with a negative ISH assay, BC is considered HER2-low (or HER2-negative). Breast tumours are tested for both oestrogen receptors (ER) and progesterone receptors (PR). About 74 % of all BCs are both HR-positive (HR+) and HER2-negative. In England, adults with stage 4 breast cancer, that were diagnosed between 2012-2016 and followed up to 2017, had a 66% survival rate one year after diagnosis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts